Targeting AR and AR-variants in castration-resistant prostate cancer

Active Project Grant Awarded Last action

Award ID
R01CA257370
Recipient
Awarding agency
Obligated
$6,927,180

Award facts

Assistance listing
93.395 Cancer Treatment Research
Completion date 95% complete
Originally
Funding
  • $6,532,074.00 Federal
  • $395,106.00 Non-federal
Place of performance
Texas, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Current AR inhibitors (enzalutamide and abiraterone) inhibit either the conversion of androgen to dihydrotestosterone (DHT), block androgen binding to androgen receptor (AR), or AR signaling. Although initially effective, these treatments eventually fail because of factors such as, AR-splice variants (AR-SVS) and AR responding to stimuli other than androgen. An effective way to control the emergence and treatment of castration-resistant prostate cancer (crpc) is to develop small molecules that either inhibit AR expression or promote its degradation. If there is no AR, there would be no AR signaling, regardless of whether or how much androgen or other stimuli of AR signaling are present in crpc. Our preliminary studies demonstrated that naturally occurring urolithin a (uroa) inhibited the AR signaling and selectively suppressed the growth of AR-positive (AR+: IC50 ~35 m) but not AR-negative (AR-: IC50 ~70 ΜM) crpc in both in vitro and in vivo models (50 MG/KG/body weight). As higher concentrations of uroa are required to suppress crpc growth, we aimed to design and develop potent uroa analogs that could selectively inhibit AR activation at lower concentrations (NM), are orally bioavailable and suppress the growth of crpc. The subsequent development of a series of uroa analogs and structure-activity relationship (SAR) studies led to the identification of two novel lead compounds ASR-600 and ASR-603 (US provisional 62/941588) which demonstrated better efficacy (NM) than uroa (ASR-600: >40-fold and ASR-603: >12-fold) in inhibiting AR signaling in crpc cell lines. Molecular studies suggest these two asrs inhibit both AR and AR-SVS expression via ubiquitination and degradation within the cytosol. Molecular dynamic (MD) system simulation studies, biophysical analysis based on nuclear magnetic resonance (NMR), and thermal shift assays showed that these small molecules bind to the n-terminal domain (NTD) of AR and block the activation of both AR and AR-SV. At physiologically achievable concentrations, ASR-600 abrogated AR+ and AR-SV (C4-2B and 22RV1) tumor growth in xenografts. Based on our preliminary results, we hypothesized that 'rationally designed asrs will effectively inhibit and/or promote the degradation of both AR and AR-SV expression by directly targeting the AR-NTD and inhibit the growth of crpc. We will test this hypothesis with the following specific aims. Aim 1. Investigate the mechanism of action of asrs on AR+ crpc cells. Aim 2. Determine in vivo signaling mechanism of AR and AR-SVS expression and optimize the dose of asrs. Aim 3. Determine the therapeutic efficacy of the asrs to inhibit crpc growth in orthotopic and patient-derived xenograft (PDX) models. The proposed studies will elucidate the mechanism of action of the asrs and lead to a better understanding of the chemotherapeutic properties of these compounds against crpc.

Transactions

Action Federal Non-federal Date
Amendment $0 $0
Amendment $45,018 $0
Amendment $45,018 $0
Amendment $405,161 $0
Amendment $405,161 $0
Amendment $405,161 $0
Amendment $22,780 $0
Amendment $22,780 $0
Amendment $22,780 $0
Amendment $410,049 $0
Amendment $410,049 $0
Amendment $410,049 $0
Amendment $410,049 $0
Amendment $448,531 $0
Amendment $448,531 $0
Amendment $448,531 $0
Amendment $448,531 $0
Amendment $36,615 $0
Amendment $36,615 $0
Amendment $36,615 $0
Amendment $411,919 $0
Amendment $411,919 $0
Amendment $395,105 $0
Amendment -$478,628 $0
Amendment $395,105 $395,105
Amendment -$478,628 -$478,628
Amendment $478,629 $0
Original award $478,629 $478,629
Show all 28

Subawards

Subrecipient Amount Awarded
The Pennsylvania State University Penn State University: Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer Amend 5-6 $180,095
Subrecipient not on record University of Louisville: Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer $11,739
Subrecipient not on record Sub w/ University of Louisville: Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer AMENDMENT 5 $705
Subrecipient not on record Sub w/ University of Louisville: Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer AMENDMENT 4 $10,699
Subrecipient not on record Sub w/ University of Louisville: Targeting AR and AR-Variants in Castration-Resistant Prostate Cancer Initial through Amendment 3 (equals >30,000) $33,686

Quick answers

Who received award R01CA257370?

R01CA257370 was awarded to Texas A & M University System Health Science Center by National Cancer Institute (National Institutes of Health) on February 1, 2021.

How much is award R01CA257370 worth?

$6,927,180 has been obligated on R01CA257370: $6,532,074 in federal funding and $395,106 in non-federal funding.

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login